Literature DB >> 1724651

Species differences between [3H] substance P binding in rat and guinea-pig shown by the use of peptide agonists and antagonists.

V Fardin1, C Garret.   

Abstract

The affinities of various substance P agonists and antagonists for NK1 receptors in rat and guinea-pig tissues were compared. Striking species differences were observed. Both septide and [D-Pro4,D-Trp7,9]SP-(4-11) possessed much higher affinity for sites in the guinea-pig (brain and ileum) than for sites in the rat brain. These results could be explained by differences in the structure of the NK1 receptor according to the species, although the existence of various subtypes of NK1 binding sites in the two species cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1724651     DOI: 10.1016/0014-2999(91)90350-y

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  FR 113680: a novel tripeptide substance P antagonist with NK1 receptor selectivity.

Authors:  H Morimoto; M Murai; Y Maeda; D Hagiwara; H Miyake; M Matsuo; T Fujii
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

2.  Pharmacological profile of a high affinity dipeptide NK1 receptor antagonist, FK888.

Authors:  T Fujii; M Murai; H Morimoto; Y Maeda; M Yamaoka; D Hagiwara; H Miyake; N Ikari; M Matsuo
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

3.  Comparative behavioural profile of centrally administered tachykinin NK1, NK2 and NK3 receptor agonists in the guinea-pig.

Authors:  O Piot; J Betschart; I Grall; S Ravard; C Garret; J C Blanchard
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

4.  Demonstration of a 'septide-sensitive' inflammatory response in rat skin.

Authors:  A Ahluwalia; S Giuliani; C A Maggi
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

5.  Characterization of NK1 and NK2 tachykinin receptors in guinea-pig and rat bronchopulmonary and vascular systems.

Authors:  A Floch; V Fardin; I Cavero
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.